Telehealth Prescribing: Navigating the State-Level Fragmentation

The pandemic-era flexibility that reshaped telehealth prescribing for controlled substances has been subject to ongoing extensions, creating a dynamic and complex regulatory environment. This shift directly impacts the operational viability and investment thesis for national telepsychiatry providers, demanding a sophisticated understanding of a fragmenting state-level field.

The Unwinding of Federal Waivers and the Reassertion of the Ryan Haight Act

Federal waivers, initially implemented during the COVID-19 public health emergency (PHE), allowed for the prescribing of controlled substances via telehealth without an initial in-person medical evaluation, temporarily suspending a core requirement of the Ryan Haight Online Pharmacy Consumer Protection Act of 2008. These flexibilities have since been extended multiple times, with the latest extension allowing DEA-registered practitioners to continue prescribing Schedule II-V controlled substances via telemedicine without an initial in-person medical evaluation through December 31, 2026. This ongoing reprieve has facilitated continued access to mental health services, particularly for conditions requiring Schedule II-V medications. Meanwhile, the DEA has been actively working to re-establish a more structured regulatory environment. The DEA submitted a final rule on telehealth prescribing of controlled substances to the White House for regulatory review on August 25, 2026, with a final rule expected in November 2026. These proposed rules, which have seen multiple iterations and extensions for public comment, underscore a clear intention to return to a framework that emphasizes patient safety and prevents diversion, while still attempting to integrate the proven benefits of telehealth. This regulatory tightening creates a dynamic tension: how can national telehealth platforms maintain broad access while working through a patchwork of state-specific mandates? The American Telemedicine Association (ATA) has consistently advocated for a more harmonized approach, emphasizing that overly restrictive rules could severely limit access to care, particularly in rural and underserved areas. American Telemedicine Association policy briefs on telehealth prescribing

Operational Friction: Case Studies from Talkspace and Cerebral

The reassertion of state-level oversight, often mirroring or exceeding federal restrictions, has created significant operational barriers for large-scale telepsychiatry platforms. Companies like Talkspace and Cerebral, which scaled rapidly during the PHE by using the federal waivers, now face the intricate challenge of adapting their service models to a state-by-state mosaic of requirements. Consider the operational impact:

• Talkspace: As a publicly traded entity, Talkspace operates across numerous states, offering virtual therapy and psychiatry. The fragmentation means that their clinical protocols, practitioner onboarding, and patient intake processes must be carefully tailored to each state’s regulations. For instance, the number of states requiring an in-person visit for controlled substances varies significantly, forcing Talkspace to either limit services in certain jurisdictions or establish complex referral networks. This directly impacts their total addressable market (TAM) and necessitates substantial investment in compliance infrastructure.
• Cerebral: This platform, which faced intense scrutiny for its prescribing practices during the PHE, particularly concerning stimulants, exemplifies the high-stakes environment. While Cerebral has made efforts to bolster its compliance framework, the evolving state field means that past operational models are no longer viable. The necessity of adhering to varying state medical board guidelines for initial consultations, follow-up frequency, and documentation for controlled substance prescribing introduces significant overhead and potential for regulatory missteps. This complexity can lead to algorithmic drift in their operational models, requiring constant recalibration of their internal systems to prevent non-compliance.

The core issue for these national providers is that a “one-size-fits-all” approach to prescribing controlled substances via telehealth is no longer feasible. Each state’s interpretation of “established patient-provider relationship” or “adequate medical evaluation” can differ, leading to a patent thicket of regulatory hurdles that must be navigated.

Strategies for De-Risking: Geographic Diversification and Compliance as a Data Moat

For both compliance officers and digital health growth investors, understanding these policy shifts is paramount. The ability to navigate this fragmented field effectively will differentiate market leaders from zombie companies. 1. Geographic Diversification with Intelligent Market Entry: Instead of attempting to offer a uniform service across all 50 states, providers must strategically identify states with more favorable or clearer telehealth prescribing regulations for controlled substances. This might involve:

• Prioritizing states that have enacted permanent telehealth legislation extending pandemic-era flexibilities.
• Focusing on states where the medical board has issued clear guidance on virtual prescribing, reducing ambiguity.
• Developing a tiered service model, where controlled substances are prescribed only in states where it’s fully compliant, while other mental health services remain broadly available.

This approach treats regulatory compliance not as a barrier, but as a strategic competitive advantage. Companies that can demonstrate strong, state-specific compliance frameworks will build a data moat of trust and operational integrity, making them more attractive to both patients and investors. 2. Proactive Engagement and Policy Advocacy: While individual companies can adapt, the broader industry benefits from collective action. Supporting organizations like the American Telemedicine Association in their advocacy for federal harmonization or clear interstate compacts is important. Investors should look for companies that are not just reactive to policy, but are actively contributing to shaping a more predictable regulatory future. 3. Investment in Strong QMS and GMLP for Compliance: The era of rapid scaling without stringent quality management systems (QMS) is over, especially for companies dealing with controlled substances. Investors performing technical due diligence should scrutinize whether a company’s operations align with ISO 13485 standards and Good Machine Learning Practice (GMLP) principles, even if not directly applicable to a SaMD. This signals a mature approach to risk management and operational excellence. FDA guidance on GMLP 4. Clinical Decision Support (CDS) vs. Diagnostic AI in Prescribing: The distinction between a clinical decision support tool and a diagnostic AI becomes critical. While AI can assist prescribers in identifying appropriate controlled substance candidates or monitoring for diversion, the ultimate responsibility and regulatory burden lie with the licensed clinician. Companies developing AI to aid in this process must clearly define their product’s regulatory classification to avoid missteps.

Methodology and Source Note

This analysis is grounded in a review of recent DEA Federal Register filings concerning proposed rules for telehealth prescribing of controlled substances, alongside policy briefs and advocacy positions articulated by the American Telemedicine Association. Further insights are drawn from monitoring state medical board legislative trackers, which reveal the varied approaches states are taking as federal waivers recede. DEA Federal Register proposed rules The operational challenges discussed are informed by public statements and regulatory actions related to prominent telepsychiatry providers. The evolving field of state-level telehealth prescribing regulations for controlled substances is a defining challenge for the digital health sector. For compliance officers, it demands careful attention to detail and a dynamic understanding of jurisdictional nuances. For investors, it redefines the risk profile and growth potential of telepsychiatry platforms, favoring those with strong, adaptable compliance strategies and a clear path to geographic diversification. The companies that thrive will be those that view regulatory rigor not as an impediment, but as a foundation of sustainable, trustworthy, and scalable care delivery.